Cytogenetics Laboratory, Royal Hobart Hospital, Tasmania, Australia.
Department of Haematology, Royal Hobart Hospital, Tasmania, Australia.
Genes Chromosomes Cancer. 2018 May;57(5):260-267. doi: 10.1002/gcc.22527. Epub 2018 Feb 19.
Chromosome abnormalities detected during cytogenetic investigations for B-cell malignancy offer prognostic information that can have wide ranging clinical impacts on patients. These impacts may include monitoring frequency, treatment type, and disease staging level. The use of the synthetic oligonucleotide DSP30 combined with interleukin 2 (IL2) has been described as an effective mitotic stimulant in B-cell disorders, not only in chronic lymphocytic leukemia (CLL) but also in a range of other B-cell malignancies. Here, we describe the comparison of two B-cell mitogens, lipopolysaccharide (LPS), and DSP30 combined with IL2 as mitogens in a range of common B-cell disorders excluding CLL. The results showed that DSP30/IL2 was an effective mitogen in mature B-cell disorders, revealing abnormal cytogenetic results in a range of B-cell malignancies. The abnormality rate increased when compared to the use of LPS to 64% (DSP30/IL2) from 14% (LPS). In a number of cases the disease burden was proportionally very low, less than 10% of white cells. In 37% of these cases, the DSP30 culture revealed abnormal results. Importantly, we also obtained abnormal conventional cytogenetics results in 3 bone marrow cases in which immunophenotyping showed an absence of an abnormal B-cell clone. In these cases, the cytogenetics results correlated with the provisional diagnosis and altered their staging level. The use of DSP30 and IL2 is recommended for use in many B-cell malignancies as an effective mitogen and their use has been shown to enable successful culture of the malignant clone, even at very low levels of disease.
在针对 B 细胞恶性肿瘤的细胞遗传学研究中检测到的染色体异常提供了预后信息，这些信息可能对患者产生广泛的临床影响。这些影响可能包括监测频率、治疗类型和疾病分期水平。已经描述了使用合成寡核苷酸 DSP30 与白细胞介素 2（IL2）联合作为 B 细胞疾病的有效有丝分裂刺激物，不仅在慢性淋巴细胞白血病（CLL）中，而且在一系列其他 B 细胞恶性肿瘤中也是如此。在这里，我们比较了两种 B 细胞有丝分裂原，脂多糖（LPS）和与 IL2 联合使用的 DSP30，作为排除 CLL 以外的一系列常见 B 细胞疾病的有丝分裂原。结果表明，DSP30/IL2 是成熟 B 细胞疾病的有效有丝分裂原，揭示了一系列 B 细胞恶性肿瘤中的异常细胞遗传学结果。与使用 LPS 相比，异常率从 14%（LPS）增加到 64%（DSP30/IL2）。在许多情况下，疾病负担相对较低，白细胞比例不到 10%。在这些病例中的 37%，DSP30 培养显示异常结果。重要的是，我们还在 3 例骨髓病例中获得了异常的常规细胞遗传学结果，免疫表型显示不存在异常 B 细胞克隆。在这些情况下，细胞遗传学结果与暂定诊断相关，并改变了它们的分期水平。建议在许多 B 细胞恶性肿瘤中使用 DSP30 和 IL2 作为有效的有丝分裂原，并且已经证明它们的使用能够成功培养恶性克隆，即使在疾病水平非常低的情况下也是如此。
